AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TAK · NYSE · Drug Manufacturers - Specialty & Generic

Takeda (ADR) (TAK)

Develops prescription medicines across gastrointestinal disease, rare disease, plasma therapies, oncology, neuroscience, and vaccines.

$18.89

After hours−0.06 (−0.34%)

At close$18.96(+0.34%)

Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast
Defense WorldSep 16
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking AlphaSep 14
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Business WireSep 14
US FDA approves Takeda, Protagonist's drug for rare blood cancer
ReutersAug 28Clinical
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Business WireAug 24Clinical
Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern
Seeking AlphaAug 7
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval
BenzingaAug 6
U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Business WireAug 5
US FDA approves Takeda's sleep disorder pill
ReutersAug 5
Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript
Seeking AlphaJul 30
Takeda Pharmaceutical Q1 Earnings Call Highlights
MarketBeatJul 30
Arrowstreet Capital Limited Partnership Sells 2,566,536 Shares of Takeda Pharmaceutical Co. $TAK
Defense WorldJul 28
Takeda Pharmaceutical (TAK) to Announce Quarterly Earnings on Thursday
Defense WorldJul 23
Takeda's QDENGA becomes first dengue vaccine approved in India
ReutersJul 20
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
BenzingaJul 17
Takeda's Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Business WireJul 16
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
Business WireJul 12
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
Business WireJun 24
New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
Business WireJun 15
Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
Business WireJun 11